Korea UCB

UCB Korea is the South Korean subsidiary of the global biopharmaceutical company UCB, specializing in neurology and immunology. The company is a leader in the Korean epilepsy market, providing essential treatments such as Keppra, Vimpat, and Briviact. In the immunology sector, UCB Korea markets Cimzia for various inflammatory conditions and has recently expanded its portfolio with the introduction of Bimekizumab for psoriasis. Additionally, the company collaborates with Amgen to provide Evenity for osteoporosis patients in Korea. UCB Korea is committed to delivering innovative medicines and patient-centric solutions, leveraging its global R&D pipeline to address high unmet medical needs in the region.